KR102279629B1 - 암에 대한 멜플루펜 용량 투여 요법 - Google Patents

암에 대한 멜플루펜 용량 투여 요법 Download PDF

Info

Publication number
KR102279629B1
KR102279629B1 KR1020187014234A KR20187014234A KR102279629B1 KR 102279629 B1 KR102279629 B1 KR 102279629B1 KR 1020187014234 A KR1020187014234 A KR 1020187014234A KR 20187014234 A KR20187014234 A KR 20187014234A KR 102279629 B1 KR102279629 B1 KR 102279629B1
Authority
KR
South Korea
Prior art keywords
melflufen
dose
patients
administered
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187014234A
Other languages
English (en)
Korean (ko)
Other versions
KR20180087254A (ko
Inventor
자콥 린드버그
Original Assignee
온코펩타이드즈 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102279629(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 온코펩타이드즈 아베 filed Critical 온코펩타이드즈 아베
Priority to KR1020217022171A priority Critical patent/KR20210092327A/ko
Publication of KR20180087254A publication Critical patent/KR20180087254A/ko
Application granted granted Critical
Publication of KR102279629B1 publication Critical patent/KR102279629B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187014234A 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법 Active KR102279629B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217022171A KR20210092327A (ko) 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1521217.8 2015-12-01
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022171A Division KR20210092327A (ko) 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법

Publications (2)

Publication Number Publication Date
KR20180087254A KR20180087254A (ko) 2018-08-01
KR102279629B1 true KR102279629B1 (ko) 2021-07-20

Family

ID=55177548

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187014234A Active KR102279629B1 (ko) 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법
KR1020217022171A Withdrawn KR20210092327A (ko) 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217022171A Withdrawn KR20210092327A (ko) 2015-12-01 2016-12-01 암에 대한 멜플루펜 용량 투여 요법

Country Status (27)

Country Link
US (3) US20180369141A1 (enExample)
EP (3) EP3383385B2 (enExample)
JP (2) JP6878431B2 (enExample)
KR (2) KR102279629B1 (enExample)
CN (1) CN108289876A (enExample)
AU (2) AU2016363591B2 (enExample)
BR (1) BR112018010012A8 (enExample)
CA (1) CA3003102C (enExample)
CY (1) CY1123469T1 (enExample)
DK (1) DK3383385T4 (enExample)
ES (1) ES2828033T5 (enExample)
FI (1) FI3383385T4 (enExample)
GB (1) GB201521217D0 (enExample)
HR (1) HRP20201632T4 (enExample)
HU (1) HUE051525T2 (enExample)
IL (2) IL259101A (enExample)
LT (1) LT3383385T (enExample)
MX (2) MX384724B (enExample)
PL (1) PL3383385T5 (enExample)
PT (1) PT3383385T (enExample)
RS (1) RS60986B2 (enExample)
RU (2) RU2734930C2 (enExample)
SG (1) SG11201803551YA (enExample)
SI (1) SI3383385T2 (enExample)
SM (1) SMT202000567T1 (enExample)
WO (1) WO2017093443A1 (enExample)
ZA (2) ZA201802816B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116198A1 (en) * 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
CA3127928A1 (en) * 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
EP3946309A1 (en) 2019-04-03 2022-02-09 Oncopeptides AB Treatment of al amyloidosis with melflufen
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
JP2024524552A (ja) * 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
US20140302014A1 (en) 2013-04-08 2014-10-09 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
ES2930140T3 (es) * 2011-04-28 2022-12-07 Oncopeptides Ab Preparación liofilizada de dipéptidos citotóxicos
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
US20140302014A1 (en) 2013-04-08 2014-10-09 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood, 124(21), 2123, 2014.
Clinical Cancer Research, 19(11), 3019-3031, 2013.*

Also Published As

Publication number Publication date
HUE051525T2 (hu) 2021-03-01
ZA201802816B (en) 2021-07-28
DK3383385T4 (da) 2023-11-06
GB201521217D0 (en) 2016-01-13
EP3383385B2 (en) 2023-09-06
EP3383385B1 (en) 2020-07-29
MX2018006706A (es) 2018-08-01
AU2016363591B2 (en) 2020-12-10
CY1123469T1 (el) 2022-03-24
RU2734930C2 (ru) 2020-10-26
EP3383385A1 (en) 2018-10-10
NZ742548A (en) 2023-10-27
SI3383385T1 (sl) 2020-11-30
JP6878431B2 (ja) 2021-05-26
ZA202102438B (en) 2025-08-27
SI3383385T2 (sl) 2024-01-31
ES2828033T5 (es) 2024-04-04
AU2021200436A1 (en) 2021-02-25
AU2016363591A1 (en) 2018-06-28
JP2019501881A (ja) 2019-01-24
HRP20201632T1 (hr) 2021-01-08
US20220047507A1 (en) 2022-02-17
PL3383385T3 (pl) 2021-05-04
RU2018123718A (ru) 2020-01-09
JP2021088560A (ja) 2021-06-10
EP3903777A1 (en) 2021-11-03
IL301019B1 (en) 2025-08-01
US20250144023A1 (en) 2025-05-08
SMT202000567T1 (it) 2020-11-10
IL301019A (en) 2023-05-01
LT3383385T (lt) 2020-12-28
IL259101A (en) 2018-06-28
KR20180087254A (ko) 2018-08-01
BR112018010012A2 (pt) 2018-11-21
RU2020134307A (ru) 2020-11-27
PT3383385T (pt) 2020-10-26
WO2017093443A1 (en) 2017-06-08
CN108289876A (zh) 2018-07-17
IL301019B2 (en) 2025-12-01
EP3750534A1 (en) 2020-12-16
BR112018010012A8 (pt) 2019-02-26
PL3383385T5 (pl) 2023-12-18
RS60986B1 (sr) 2020-11-30
FI3383385T4 (fi) 2023-11-01
HRP20201632T4 (hr) 2023-11-10
RU2018123718A3 (enExample) 2020-04-02
RS60986B2 (sr) 2023-12-29
CA3003102C (en) 2022-09-13
CA3003102A1 (en) 2017-06-08
SG11201803551YA (en) 2018-05-30
MX384724B (es) 2025-03-14
ES2828033T3 (es) 2021-05-25
KR20210092327A (ko) 2021-07-23
US20180369141A1 (en) 2018-12-27
DK3383385T3 (da) 2020-10-12
MX2021008738A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
KR102279629B1 (ko) 암에 대한 멜플루펜 용량 투여 요법
ES2824120T3 (es) Procedimientos de tratamiento del cáncer usando inhibidores de b-raf e inhibidores de los puntos de control inmunitario
KR102004559B1 (ko) 데시타빈 유도체 제제
CA3013467A1 (en) Compositions containing tucaresol or its analogs
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
CA3148965A1 (en) Formulations and dosages for administering a compound that inhibits mcl1 protein
US11129836B2 (en) PAR-4 agonists for the treatment of cancer
KR20240019097A (ko) 토포이소머라아제 i 억제제의 펩타이드 접합체 투여 요법
WO2022187631A1 (en) Micelle releasing thermosensitive hydrogels as a therapeutic delivery system
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
NZ742548B2 (en) Melflufen dosage regimens for cancer
HK1260696B (en) Melflufen dosage regimens for cancer
WO2019220961A1 (ja) ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180518

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201021

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20201021

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201201

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210304

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210603

GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210714

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210714

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210715

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240627

Start annual number: 4

End annual number: 4